BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Thinn MM, Hsueh CT, Hsueh CT. Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report. World J Clin Cases 2019; 7(5): 616-622 [PMID: 30863760 DOI: 10.12998/wjcc.v7.i5.616]
URL: https://www.wjgnet.com/2307-8960/full/v7/i5/616.htm
Number Citing Articles
1
Dan Yu, Xueshibojie Liu, Guanghong Han, Yan Liu, Xue Zhao, Di Wang, Xiaomin Bian, Tingting Gu, Lianji Wen. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradationCell Communication and Signaling 2019; 17(1) doi: 10.1186/s12964-019-0490-8
2
Manuel Stöth, Till Meyer, Thomas Gehrke, Rudolf Hagen, Matthias Scheich, Stephan Hackenberg, Agmal Scherzad. Discontinuation of anti‑programmed cell death protein 1 immune checkpoint inhibition after complete remission in head and neck squamous cell carcinoma: A case report and literature reviewOncology Letters 2023; 26(5) doi: 10.3892/ol.2023.14076
3
Bharti Mangla, Priya Mittal, Pankaj Kumar, Geeta Aggarwal. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trialsMedical Oncology 2024; 41(7) doi: 10.1007/s12032-024-02414-5
4
Revathy Nadhan, Priya Srinivas, M. Radhakrishna Pillai. Receptor Tyrosine KinasesAdvances in Cancer Research 2020; 147: 319 doi: 10.1016/bs.acr.2020.04.008